Key Drivers
- Strong Liquidity
- Persistent Losses
- Negative Cash Flow
AIAI Summary
CBLL's FDA/NTAP-enabled expansion into a broader point-of-care neurology platform strengthens growth potential, but at ~7x sales the investment hinges on proving that rising hospital utilization converts its 92% gross margins into operating leverage and sharply lower cash burn; investors should wait for sustained expense discipline and free-cash-flow improvement.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Losses
- •Negative Cash Flow
CBLL has strong liquidity and low leverage, but persistent losses, cash burn, declining equity, and a premium valuation make it a high-risk investment pending operating improvement.
Price Behavior
Key Price Behavior Insights:
- •Range-bound trading
- •Firm support zone
- •Resistance rejection
CBLL was range-bound over the last month, holding above $23.37–$23.63 support but fading from $25.04 resistance; a breakout above $25.04 is bullish, while a break below $23.37 weakens the setup.
Pulled back from $25.04 to $24.37 after the
Sentiment & News
Key News Insights:
- •BlackRock New Stake
- •BofA Holding Increase
- •Institutional Interest
BlackRock's new 5.1% stake and Bank of America's increased holding signal strengthening institutional interest in CeriBell.
The disclosures are a positive ownership signal for CBLL but provide no direct insight into operating fundamentals
Similar Companies in Healthcare
Other companies in the same sector with AI ratings